Clinical trial
Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir: An Investigator-initiated Randomised, Controlled, Open-label Clinical Trial (The INITIATE Study)
NCT07481175 is registered in ClinicalTrials.gov with Thomas Aagaard Rasmussen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir: An Investigator-initiated Randomised, Controlled, Open-label Clinical Trial (The INITIATE Study)
- Lead sponsor
- Thomas Aagaard Rasmussen
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 13, 2026
- Completion date
- January 31, 2030
- Enrollment
- 38 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
hiv-1